Brief: Cognition Presents Analyses From Clinical Trial Of CT1812 In Mild-To-Moderate Alzheimer's
19/07/2022 14:36
July 19 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS PRESENTING NEW ANALYSES FROM
ONGOING
CLINICAL TRIAL OF CT1812 IN MILD-TO-MODERATE ALZHEIMER’S DISEASE
* COGNITION THERAPEUTICS INC - ANALYSES DEMONSTRATE CT1812
IMPACT
ON ALZHEIMER'S DISEASE PROCESSES
Source text for Eikon: ID:nGNX9MFVMq
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB